Navigation Links
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Date:6/4/2009

onnection with the restructuring and costs associated with the restructuring. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the restructuring may result in additional costs or other negative results not currently anticipated. Moreover, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will have favorable results in the planned Phase II trial. Also, Anadys cannot provide any assurances that the FDA will concur with Anadys' proposed ANA598 Phase II trial design. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... While administrative claims and other data ... a relatively long period of time, there has ... of these ‘big data’ for comparisons of interventions ... powerful computer technology with the plethora of data ... significant promise for identifying optimal interventions for specific ...
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
(Date:7/30/2014)... Sales Horizons, a leader in sales training ... programs for companies engaged in complex B2B sales. , ... of salespeople over 25 years in market-leading Fortune 500 ... customized to address the unique sales challenges of companies ... program consists of two parts: Mastering the Complex ...
(Date:7/30/2014)... EL SEGUNDO, Calif. , July 30, 2014 ... prime contractor on the Fully Integrated Lifecycle Mission ... Aeronautics and Space Administration (NASA). Under the terms ... to Ames Research Center at Moffett Field, Calif. ... management support for bioscience flight development projects on ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2
... Inc. (NYSE Alternext US: ILI) announced today, that on ... NYSE Alternext US LLC (the "the Exchange") indicating that ... of the Exchange,s continued listing standards under Section 1003 ... Company,s failure to comply with Section 1003(a)(iii) of the ...
... innate defence system against deadly bacteria. However, how the step ... not yet known. To date, B. Pseudomallei, a ... can remain hidden in the human body for many years ... suddenly become activated and spread throughout the body, resulting in ...
... Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of ... the broad anti-viral potential of the company,s novel ... drug bavituximab can cure lethal virus infections in ... in clinical trials for the treatment of hepatitis ...
Cached Biology Technology:Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii) 2Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii) 3Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3
(Date:7/30/2014)... announced an across-the-board increase in Impact Factors for ... Journal Citation Reports (Thomson Reuters, 2014) show that ... Essays in Biochemistry , Biochemical Society ... received increases in their Impact Factors. The journals ... by Portland Press Limited. , 2014 Impact Factors ...
(Date:7/30/2014)... to create colors, nature had already perfected the process ... hues, for example. Now scientists are tapping into those ... make colored plastics. Their paper on using structure ... than dyes, to produce color appears in the ACS ... Anders Kristensen and colleagues point out that currently, plastic ...
(Date:7/30/2014)... decisions about what they eat, the Food and Drug ... the Nutrition Facts label found on nearly every food ... & Engineering News (C&EN), the weekly news magazine ... and the fight that has ensued. , Britt ... while the Nutrition Facts label has remained largely the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2
... cattle feed as a possible culprit in the long-standing ... moderately-populated agricultural region has higher levels of ozone ... densely-populated cities. The report, which explains how fermented cattle ... in ACS, Environmental Science & Technology , a ...
... N.J. -- Stevens Institute of Technology presents Research & ... Arena , Schaefer Athletic Center on Stevens campus. ... including its array of startup companies and student based ... the Institutes, focus on entrepreneurship and success in engineering ...
... Virginia Tech biologist proposes to use a physics strategy called ... where they will be sensitive to antibiotics. In medicine, ... she thumps your chest. In physics, resonance is a periodic ... of a natural system,s frequency. Sound waves are an example ...
Cached Biology News:Research & Entrepreneurship Day 2010: Engineering Innovation 2Physics strategy tested as solution for antibiotic resistance 2
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
WIF-1 (N-20)...
Biology Products: